BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

The outcome of this study could significantly influence BioNTech’s stock performance and investor sentiment, especially if the combination therapy proves more effective than the standard treatment.

BioNTech ADR earns the No. 143 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

A large retrospective study found that nearly a quarter of high-grade serous cancers occurred after missed chances to perform ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...